CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$163.1 million.
- CRISPR Therapeutics AG's Net Income towards Common Stockholders fell 10646.97% to -$163.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$614.1 million, marking a year-over-year decrease of 5052.6%. This contributed to the annual value of -$614.1 million for FY2025, which is 5053.29% down from last year.
- CRISPR Therapeutics AG's Net Income towards Common Stockholders amounted to -$163.1 million in Q4 2025, which was down 10646.97% from -$106.4 million recorded in Q3 2025.
- CRISPR Therapeutics AG's Net Income towards Common Stockholders' 5-year high stood at $759.2 million during Q2 2021, with a 5-year trough of -$208.6 million in Q2 2025.
- In the last 5 years, CRISPR Therapeutics AG's Net Income towards Common Stockholders had a median value of -$114.9 million in 2021 and averaged -$74.1 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 105287.85% in 2021, then tumbled by 23481.09% in 2024.
- CRISPR Therapeutics AG's Net Income towards Common Stockholders (Quarter) stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then tumbled by 106.47% to -$163.1 million in 2025.
- Its Net Income towards Common Stockholders was -$163.1 million in Q4 2025, compared to -$106.4 million in Q3 2025 and -$208.6 million in Q2 2025.